CSL Seqirus is a world leader in influenza vaccines.
CSL Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza, with extensive research, production expertise, and manufacturing plants in the U.S., U.K., and Australia.
Operator of a clinical-stage vaccine company intended to prevent influenza and other respiratory pathogens such as COVID-19. The company's vaccines focus on the prevention of both seasonal and pandemic influenza with a live, single replication, intranasally delivered virus which has a portion of the M2 segment deleted (M2SR), enabling healthcare professionals to prevent the spreading of influenza and pandemics.